1. Home
  2. SIDU vs ALXO Comparison

SIDU vs ALXO Comparison

Compare SIDU & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sidus Space Inc.

SIDU

Sidus Space Inc.

N/A

Current Price

$1.93

Market Cap

243.4M

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.89

Market Cap

205.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SIDU
ALXO
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
243.4M
205.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SIDU
ALXO
Price
$1.93
$1.89
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.50
AVG Volume (30 Days)
3.1M
654.9K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
66.94
26.36
EPS
N/A
N/A
Revenue
$3,383,878.00
N/A
Revenue This Year
$171.29
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.03
52 Week High
$6.79
$2.66

Technical Indicators

Market Signals
Indicator
SIDU
ALXO
Relative Strength Index (RSI) 36.53 46.38
Support Level $1.73 $1.90
Resistance Level $3.12 $2.17
Average True Range (ATR) 0.11 0.10
MACD -0.03 -0.01
Stochastic Oscillator 4.65 41.07

Price Performance

Historical Comparison
SIDU
ALXO

About SIDU Sidus Space Inc.

Sidus Space Inc is a space and defense technology company with core capabilities that include dual use satellite manufacturing & technology integration, AI products and services, space and defense hardware components and space-based data solutions. The company generates revenue through a combination of: Satellite platform sales and customization, Payload hosting and mission services, Engineering and systems integration services, and Space and defense hardware manufacturing. The firm supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers. The firm generates revenue principally from satellite platform and payload hosting contracts, manufacturing and engineering services, mission operations, and sales of proprietary hardware products.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: